What is the Best Antimicrobial Treatment for Severe Community-Acquired Pneumonia (Including the Role of Steroids and Statins and Other Immunomodulatory Agents)

Oriol Sibila; Marcos I. Restrepo; Antonio Anzueto

doi:10.1016/j.idc.2012.11.014

What is the Best Antimicrobial Treatment for Severe Community-Acquired Pneumonia (Including the Role of Steroids and Statins and Other Immunomodulatory Agents)

Oriol Sibila
, Marcos I. Restrepo
, Antonio Anzueto

Department of Medicine

Research output: Contribution to journal › Review article › peer-review

24 Scopus citations

Abstract

Community-acquired pneumonia (CAP) is the leading cause of death from infectious diseases in the United States. The mortality rate due to severe CAP has shown little improvement over the past few years, with a rate as high as 50% mainly in patients admitted to intensive care units. Death and adverse outcomes from CAP result from a complex interplay between the pathogen and the host. Several therapies have been tested in patients with severe CAP in recent years. This article reviews recent data regarding different treatments including antimicrobials and adjunctive therapies in patients with severe CAP.

Original language	English (US)
Pages (from-to)	133-147
Number of pages	15
Journal	Infectious disease clinics of North America
Volume	27
Issue number	1
DOIs	https://doi.org/10.1016/j.idc.2012.11.014
State	Published - Mar 2013

Keywords

Community-acquired infections
Intensive care unit
Pneumonia
Therapeutics

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases

Access to Document

10.1016/j.idc.2012.11.014

Cite this

What is the Best Antimicrobial Treatment for Severe Community-Acquired Pneumonia (Including the Role of Steroids and Statins and Other Immunomodulatory Agents). / Sibila, Oriol; Restrepo, Marcos I.; Anzueto, Antonio.
In: Infectious disease clinics of North America, Vol. 27, No. 1, 03.2013, p. 133-147.

Research output: Contribution to journal › Review article › peer-review

@article{e9a50311f14d4c78a89ea78c2bd431c1,

title = "What is the Best Antimicrobial Treatment for Severe Community-Acquired Pneumonia (Including the Role of Steroids and Statins and Other Immunomodulatory Agents)",

abstract = "Community-acquired pneumonia (CAP) is the leading cause of death from infectious diseases in the United States. The mortality rate due to severe CAP has shown little improvement over the past few years, with a rate as high as 50\% mainly in patients admitted to intensive care units. Death and adverse outcomes from CAP result from a complex interplay between the pathogen and the host. Several therapies have been tested in patients with severe CAP in recent years. This article reviews recent data regarding different treatments including antimicrobials and adjunctive therapies in patients with severe CAP.",

keywords = "Community-acquired infections, Intensive care unit, Pneumonia, Therapeutics",

author = "Oriol Sibila and Restrepo, \{Marcos I.\} and Antonio Anzueto",

year = "2013",

month = mar,

doi = "10.1016/j.idc.2012.11.014",

language = "English (US)",

volume = "27",

pages = "133--147",

journal = "Infectious disease clinics of North America",

issn = "0891-5520",

publisher = "W.B. Saunders",

number = "1",

}

TY - JOUR

T1 - What is the Best Antimicrobial Treatment for Severe Community-Acquired Pneumonia (Including the Role of Steroids and Statins and Other Immunomodulatory Agents)

AU - Sibila, Oriol

AU - Restrepo, Marcos I.

AU - Anzueto, Antonio

PY - 2013/3

Y1 - 2013/3

N2 - Community-acquired pneumonia (CAP) is the leading cause of death from infectious diseases in the United States. The mortality rate due to severe CAP has shown little improvement over the past few years, with a rate as high as 50% mainly in patients admitted to intensive care units. Death and adverse outcomes from CAP result from a complex interplay between the pathogen and the host. Several therapies have been tested in patients with severe CAP in recent years. This article reviews recent data regarding different treatments including antimicrobials and adjunctive therapies in patients with severe CAP.

AB - Community-acquired pneumonia (CAP) is the leading cause of death from infectious diseases in the United States. The mortality rate due to severe CAP has shown little improvement over the past few years, with a rate as high as 50% mainly in patients admitted to intensive care units. Death and adverse outcomes from CAP result from a complex interplay between the pathogen and the host. Several therapies have been tested in patients with severe CAP in recent years. This article reviews recent data regarding different treatments including antimicrobials and adjunctive therapies in patients with severe CAP.

KW - Community-acquired infections

KW - Intensive care unit

KW - Pneumonia

KW - Therapeutics

UR - https://www.scopus.com/pages/publications/84873547769

UR - https://www.scopus.com/pages/publications/84873547769#tab=citedBy

U2 - 10.1016/j.idc.2012.11.014

DO - 10.1016/j.idc.2012.11.014

M3 - Review article

C2 - 23398870

AN - SCOPUS:84873547769

SN - 0891-5520

VL - 27

SP - 133

EP - 147

JO - Infectious disease clinics of North America

JF - Infectious disease clinics of North America

IS - 1

ER -

What is the Best Antimicrobial Treatment for Severe Community-Acquired Pneumonia (Including the Role of Steroids and Statins and Other Immunomodulatory Agents)

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this